2024
Considerations when prescribing opioid agonist therapies for people living with HIV
Tarfa A, Lier A, Shenoi S, Springer S. Considerations when prescribing opioid agonist therapies for people living with HIV. Expert Review Of Clinical Pharmacology 2024, 17: 549-564. PMID: 38946101, PMCID: PMC11299801, DOI: 10.1080/17512433.2024.2375448.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidAnti-HIV AgentsBuprenorphineDelayed-Action PreparationsDelivery of Health CareDrug InteractionsHealth Services AccessibilityHIV InfectionsHumansMethadoneNaltrexoneNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPre-Exposure ProphylaxisUnited StatesConceptsOpioid agonist therapyOpioid use disorderAntiretroviral therapyAgonist therapyDiagnosed OUDOpioid use disorder managementUse disorderTreatment of opioid use disorderExtended-release naltrexonePotential drug interactionsOpioid use disorder treatmentPrescribed opioid agonist therapyLong-acting formulationPre-exposure prophylaxisOUD outcomesImprove HIV preventionIntersection of HIVOpioid antagonistHIV outcomesHIV epidemicOpioidHIVOpioid use disorder servicesPWHHIV preventionMissed Opportunities for Preexposure Prophylaxis Initiation in Hospitalized Persons With Opioid Use Disorder and Infectious Diseases
Parchinski K, Neirinckx V, Frank C, Di Paola A, Tarfa A, Shenoi S, Vander WyK B, Roth P, Ghantous T, Wegman M, Strong M, Levin F, Brady K, Nunes E, Litwin A, Springer S. Missed Opportunities for Preexposure Prophylaxis Initiation in Hospitalized Persons With Opioid Use Disorder and Infectious Diseases. Open Forum Infectious Diseases 2024, 11: ofae366. PMID: 39022389, PMCID: PMC11252843, DOI: 10.1093/ofid/ofae366.Peer-Reviewed Original ResearchHIV Risk and Interest in Preexposure Prophylaxis in Justice-Involved Persons - Volume 30, Supplement—March 2024 - Emerging Infectious Diseases journal - CDC
Nijhawan A, Pulitzer Z, Torres B, Noreen N, Schultheis A, Frank C, Colon R, Brooks R, Proffitt R, Pankow J, Bennett A, Salyards M, Kuo I, Knight K, Springer S. HIV Risk and Interest in Preexposure Prophylaxis in Justice-Involved Persons - Volume 30, Supplement—March 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: s68-s74. PMID: 38561803, PMCID: PMC10986824, DOI: 10.3201/eid3013.230739.Peer-Reviewed Original ResearchConceptsHIV riskAssess HIV risk factorsPreexposure prophylaxisPartners of unknown HIV statusMobile health unitReport injection drug useUnknown HIV statusPerceived HIV riskRisk factorsHIV risk factorsRandomized controlled trialsPatient navigationPrEP indicationsInjection drug useHealth unitsJustice-involved personsHIV medicationsHIV statusCondomless sexPrEPEducational effortsDrug useHIVRiskPersons
2023
Integrated Care Models: HIV and Substance Use
Hill K, Kuo I, Shenoi S, Desruisseaux M, Springer S. Integrated Care Models: HIV and Substance Use. Current HIV/AIDS Reports 2023, 20: 286-295. PMID: 37698755, PMCID: PMC11034717, DOI: 10.1007/s11904-023-00667-9.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersSubstance useIntegrated careRecent HIV outbreaksHIV viral suppressionMultidisciplinary care teamHIV virologic suppressionOpioid use disorderRisk of HIVHarm reduction programsSubstance use treatmentEvidence-based strategiesVirologic suppressionViral suppressionHIV outbreakCare teamProvider trainingHIVOnward transmissionHealth outcomesCare servicesClinic leadershipCare integrationMedical literature
2021
Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence
Schultheis A, Sanchez M, Pedersen S, Kyriakides T, Ho YC, Kluger Y, Springer SA. Design and implementation of a cohort study of persons living with HIV infection who are initiating medication treatment for opioid use disorder to evaluate HIV-1 persistence. Contemporary Clinical Trials Communications 2021, 24: 100866. PMID: 34825103, PMCID: PMC8605182, DOI: 10.1016/j.conctc.2021.100866.Peer-Reviewed Original ResearchOpioid use disorderHIV-1 persistenceHIV persistenceCohort studyHIV infectionMedication treatmentLimited bloodUse disordersProviral landscapeDSM-5 opioid-use disordersExtended-release naltrexoneProspective cohort studyHIV-1 expressionPartial agonist buprenorphineLongitudinal studyHIV continuumMonth 3Clonal expansion dynamicsMOUDDifferential biological effectsStudy participantsHIVMolecular virologyBloodBuprenorphineGender Differences among Criminal Justice-Involved Persons Living with HIV Interested in Extended-Release Naltrexone Treatment
Biondi BE, Frank CA, Forray A, Springer SA. Gender Differences among Criminal Justice-Involved Persons Living with HIV Interested in Extended-Release Naltrexone Treatment. Substance Use & Addiction Journal 2021, 42: 905-911. PMID: 33750285, PMCID: PMC8455717, DOI: 10.1080/08897077.2021.1900984.Peer-Reviewed Original ResearchConceptsSubstance use disordersOpioid use disorderMedication treatmentUse disordersAlcohol use disorderMental health severityXR-NTXAntiretroviral therapyDouble-blind placebo-controlled trialExtended-release naltrexone treatmentExtended-release naltrexonePlacebo-controlled trialCriminal justice-involved personsHealth severityGender differencesCocaine use disorderDrug use severityJustice-involved personsClinical characteristicsART adherenceNaltrexone treatmentTreatment outcomesHigh prevalenceCocaine useHIVLinking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions
Taweh N, Schlossberg E, Frank C, Nijhawan A, Kuo I, Knight K, Springer SA. Linking criminal justice-involved individuals to HIV, Hepatitis C, and opioid use disorder prevention and treatment services upon release to the community: Progress, gaps, and future directions. International Journal Of Drug Policy 2021, 96: 103283. PMID: 34020864, PMCID: PMC8568621, DOI: 10.1016/j.drugpo.2021.103283.Peer-Reviewed Original ResearchConceptsMobile health unitOpioid use disorderHepatitis COUD preventionTreatment servicesInfectious diseasesHepatitis C virus (HCV) managementOpioid use disorder preventionCJ-involved individualsCriminal justice-involved individualsCJ systemHarm reduction servicesImproving HIVCare cascadePatient navigationJustice-involved individualsHealth unitsUse disordersHIVReduction servicesSubstance usePreventionDisorder preventionCommunity agenciesTreatmentDesign and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder
Biondi BE, Mohanty S, Vander Wyk BV, Montgomery RR, Shaw AC, Springer SA. Design and implementation of a prospective cohort study of persons living with and without HIV infection who are initiating medication treatment for opioid use disorder. Contemporary Clinical Trials Communications 2021, 21: 100704. PMID: 33490708, PMCID: PMC7807244, DOI: 10.1016/j.conctc.2021.100704.Peer-Reviewed Original ResearchOpioid use disorderProspective cohort studyHIV infectionCohort studyMedication treatmentUse disordersDSM-5 opioid-use disordersLongitudinal studyBiological effectsHIV continuumMonth 6Immune responseDifferential biological effectsMOUDHIVSystems biology approachInfectionTreatmentDSM-5DisordersPersonsBiology approachMedicationsBuprenorphineMethadone
2020
Do I Have HIV or Not? Lack of RNA Detection and the Case for Sensitive DNA Testing
Springer SA, Masciotra S, Johnson JA, Campbell S. Do I Have HIV or Not? Lack of RNA Detection and the Case for Sensitive DNA Testing. Open Forum Infectious Diseases 2020, 7: ofaa478. PMID: 33204760, PMCID: PMC7651562, DOI: 10.1093/ofid/ofaa478.Peer-Reviewed Original ResearchHazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam.
Wagman JA, Wynn A, Matsuzaki M, Gnatienko N, Metsch LR, Del Rio C, Feaster DJ, Nance RM, Whitney BM, Delaney JAC, Kahana SY, Crane HM, Chandler RK, Elliott JC, Altice F, Lucas GM, Mehta SH, Hirsch-Moverman Y, El-Sadr WM, Vu Q, Nguyen Thanh B, Springer SA, Tsui JI, Samet JH. Hazardous alcohol use, antiretroviral therapy receipt, and viral suppression in people living with HIV who inject drugs in the United States, India, Russia, and Vietnam. AIDS 2020, 34: 2285-2294. PMID: 33048870, PMCID: PMC7951611, DOI: 10.1097/qad.0000000000002716.Peer-Reviewed Original ResearchConceptsHazardous alcohol useFormer injection drug useART receiptViral suppressionInjection drug useLow-middle income countriesAlcohol useAntiretroviral therapyMiddle-income countriesDrug useAlcohol Use Disorders Identification Test (AUDIT) scoresHIV viral suppressionAlcohol Use Disorders Identification TestDisorders Identification TestTherapy receiptHIV continuumMean ageHigh-income countriesCare outcomesLogistic regressionUpper middle-income countriesPLHIVDrugsIdentification TestHIVPreventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose.
Strathdee SA, Kuo I, El-Bassel N, Hodder S, Smith LR, Springer SA. Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose. AIDS 2020, 34: 1997-2005. PMID: 32826391, PMCID: PMC7606503, DOI: 10.1097/qad.0000000000002673.Peer-Reviewed Original ResearchConceptsHIV outbreakRecent HIV outbreaksEpidemiology of HIVEvidence-based interventionsOpioid disordersHIV infectionTreatment cascadeEvidence-based responsesHIV epidemicOpioid epidemicHIV preventionPrescription opiatesHIVPWIDSynthetic opioidsDrugsPublic healthInfectionPreventionHigher proportionUnited StatesEpidemicOutbreakEditorial reviewRelentless cycleLessons Learned from the Response to the Human Immunodeficiency Virus Epidemic that Can Inform Addressing the Opioid Epidemic
Springer SA, del Rio C. Lessons Learned from the Response to the Human Immunodeficiency Virus Epidemic that Can Inform Addressing the Opioid Epidemic. Infectious Disease Clinics Of North America 2020, 34: 637-647. PMID: 32782106, PMCID: PMC7414693, DOI: 10.1016/j.idc.2020.06.015.Peer-Reviewed Original Research
2019
Reduced Sexual Risk Behaviors Among Persons With HIV After Release From the Criminal Justice System
Biondi BE, Frank C, Horn BP, Springer SA. Reduced Sexual Risk Behaviors Among Persons With HIV After Release From the Criminal Justice System. Open Forum Infectious Diseases 2019, 6: ofz411. PMID: 31660369, PMCID: PMC6788338, DOI: 10.1093/ofid/ofz411.Peer-Reviewed Original ResearchHIV viral suppressionViral suppressionMonths 1Double-blind placebo-controlled trialCondom usePlacebo-controlled trialExtended-release naltrexoneOpioid use disorderSelf-reported sexual activityHIV prevalenceHIV transmissionSexual intercourse eventsGeneral populationUse disordersSex partnersHIVSexual partnersAlcohol useSexual activityIntercourse eventsMonthsSexRiskMonths postreleaseSuppressionMedications for Treatment of Opioid Use Disorder among Persons Living with HIV
Fanucchi L, Springer SA, Korthuis PT. Medications for Treatment of Opioid Use Disorder among Persons Living with HIV. Current HIV/AIDS Reports 2019, 16: 1-6. PMID: 30684117, PMCID: PMC6420833, DOI: 10.1007/s11904-019-00436-7.Peer-Reviewed Original ResearchConceptsOpioid use disorderExtended-release naltrexoneHIV treatment outcomesHIV viral suppressionViral suppressionUse disordersAntiretroviral therapyTreatment outcomesCurrent US opioid epidemicOptimal HIV treatment outcomesUS opioid epidemicOverall mortalityHIV outbreakHIV treatmentOpioid epidemicMOUDHIVMedicationsDisordersNaltrexoneDelivery characteristicsTherapyTreatmentIncarcerated settingsOutcomes
2018
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppressionRisk behaviors and HIV care continuum outcomes among criminal justice-involved HIV-infected transgender women and cisgender men: Data from the Seek, Test, Treat, and Retain Harmonization Initiative
Beckwith CG, Kuo I, Fredericksen RJ, Brinkley-Rubinstein L, Cunningham WE, Springer SA, Loeliger KB, Franks J, Christopoulos K, Lorvick J, Kahana SY, Young R, Seal DW, Zawitz C, Delaney JA, Crane HM, Biggs ML. Risk behaviors and HIV care continuum outcomes among criminal justice-involved HIV-infected transgender women and cisgender men: Data from the Seek, Test, Treat, and Retain Harmonization Initiative. PLOS ONE 2018, 13: e0197730. PMID: 29787580, PMCID: PMC5963777, DOI: 10.1371/journal.pone.0197730.Peer-Reviewed Original ResearchConceptsHIV care continuum outcomesCare continuum outcomesContinuum outcomesTransgender womenCisgender menViral suppressionHIV riskCondomless sexRisk behaviorsSexual partnersExchange sexMean percent adherenceCrack/cocaineMultiple sexual partnersRisk reduction interventionsHigh rateHIV continuumHIV infectionPercent adherenceCare outcomesHIVReduction interventionsCocaine useDrug abuseCJ systemExtended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomes
2017
Corrigendum to “Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community” [Contemp. Clin. Trials (2014) 209–218]
Springer SA, Altice FL, Herme M, Di Paola A. Corrigendum to “Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community” [Contemp. Clin. Trials (2014) 209–218]. Contemporary Clinical Trials 2017, 57: 98. PMID: 28341227, DOI: 10.1016/j.cct.2017.03.008.Peer-Reviewed Original ResearchCorrigendum to ‘An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone’ [Journal of Substance Abuse Treatment 47 (2014) 35–40]
Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. Corrigendum to ‘An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone’ [Journal of Substance Abuse Treatment 47 (2014) 35–40]. Journal Of Substance Use And Addiction Treatment 2017, 77: 44. PMID: 28476270, PMCID: PMC5458355, DOI: 10.1016/j.jsat.2017.03.008.Peer-Reviewed Original ResearchGender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A “Seek, Test, Treat, and Retain” Harmonization Consortium
Loeliger KB, Biggs ML, Young R, Seal DW, Beckwith CG, Kuo I, Gordon MS, Altice FL, Ouellet LJ, Cunningham WE, Young JD, Springer SA. Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A “Seek, Test, Treat, and Retain” Harmonization Consortium. AIDS And Behavior 2017, 21: 2945-2957. PMID: 28188460, PMCID: PMC5552433, DOI: 10.1007/s10461-017-1722-9.Peer-Reviewed Original ResearchConceptsHIV risk behaviorsRisk behaviorsHIV risk reduction interventionsHIV-negative participantsHIV-positive womenHIV-positive menMultilevel mixed-effects logistic regression modelSero-discordant partnersMixed effects logistic regression modelsCondomless sexual intercourseRisk reduction interventionsLogistic regression modelsCJ populationsBehavior Assessment ToolHIV transmissionCriminal justice populationsHigher oddsHIVReduction interventionsSexual intercourseLarge-scale studiesBaseline dataInjection equipmentJustice populationsAssessment tool